298690-72-9

Basic information

• Product Name: 2-(3-Fluorophenyl)-pyrrolidine
• Synonyms: CBI-BB ZERO/004834;2-(3-FLUORO-PHENYL)-PYRROLIDINE;2-(3-FLUOROPHENYL)-PYRROLIDINE, 97+%
• CAS NO: 298690-72-9
• Molecular Formula: C₁₀H₁₂FN
• Molecular Weight: 165.21
• Product Categories: Benzenes
• Mol File: 298690-72-9.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 232.3 °C at 760 mmHg
• Flash Point: 94.3 °C
• Appearance: /
• Density: 1.078 g/cm³
• Vapor Pressure: 0.0595mmHg at 25°C
• Refractive Index: 1.515
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 9.58±0.10(Predicted)
• CAS DataBase Reference: 2-(3-Fluorophenyl)-pyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-Fluorophenyl)-pyrrolidine(298690-72-9)
• EPA Substance Registry System: 2-(3-Fluorophenyl)-pyrrolidine(298690-72-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 298690-72-9(Hazardous Substances Data)

Usage

Uses

2-(3-Fluorophenyl)pyrrolidine

InChI:InChI=1/C10H12FN/c11-9-4-1-3-8(7-9)10-5-2-6-12-10/h1,3-4,7,10,12H,2,5-6H2

Upstream product

• 451-02-5 ethyl 3-fluorobenzoate 
• 455-38-9 3-fluorobenzoic acid 
• 456-48-4 3-Fluorobenzaldehyde 
• 1196552-03-0 3-chloro-N-(3-fluorobenzylidene)propan-1-amine 
• 164737-45-5 2-(3-fluorophenyl)-Δ¹-pyrroline 

Downstream Products

• 1196546-88-9 3-(5-(2-(3-fluorophenyl)pyrrolidin-1-yl)-3H-imidazo[4,5-b]pyridin-3-yl)benzonitrile 

Relevant articles and documents

Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold

Tropomyosin receptor kinase (TRK) is an ideal target for treating cancers caused by the NTRK gene fusion. In this study, more than 60 2,4-diaminopyrimidine derivatives were prepared to understand the structure-activity relationship and confirm the rationality of the pharmacophore model reported previously. Among them, compound 19k was found to be a potent pan-TRK inhibitor that inhibits the proliferation of Km-12 cell lines. Additionally, compound 19k induced the apoptosis of Km-12 cells in a concentration-dependent manner. Western blot analysis revealed that compound 19k inhibited the phosphorylation of TRK to block downstream pathways. Compound 19k also possessed outstanding plasma stability and liver microsomal stability in vitro, with half-lives greater than 289.1 min and 145 min, respectively. Pharmacokinetic studies indicated that the oral bioavailability of compound 19k is 17.4%. These results demonstrate that compound 19k could serve as a novel lead compound for overcoming NTRK-fusion cancers.

Stereocomplementary Synthesis of Pharmaceutically Relevant Chiral 2-Aryl-Substituted Pyrrolidines Using Imine Reductases

Exploring a collection of naturally occurring imine reductases (IREDs) identified two stereocomplementary IREDs with reducing activity toward sterically hindered 2-aryl-substituted pyrrolines. Using (R)-selective ScIR and (S)-selective SvIR, various chiral 2-aryl-substituted pyrrolidines with excellent enantioselectivity (>99% ee) were stereocomplementarily synthesized in good yield (60-80%), demonstrating the feasibility of IREDs for generating pharmaceutically relevant chiral 2-aryl-substituted pyrrolidine intermediates.

COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.